Research Desk Line-up: AngioDynamics Post Earnings Coverage
LONDON, UK / ACCESSWIRE / October 3, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Skyline Medical Inc. (NASDAQ: SKLN), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=SKLN. The Company, which manufactures the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, shared announced on September 29, 2017, an update on the completion of its pending merger with CytoBioscience. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Medical Instruments & Supplies industry. Pro-TD has currently selected AngioDynamics, Inc. (NASDAQ: ANGO) for due-diligence and potential coverage as the Company reported on September 28, 2017, its financial results for Q1 FY18 which ended on August 31, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on AngioDynamics when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on SKLN; also brushing on ANGO. Go directly to your stock of interest and access today's free coverage at:
About the Skyline Medical/ CytoBioscience Merger
Skyline Medical entered into a definitive agreement for the merger with CytoBioscience on August 09, 2017. CytoBioscience, which is based in Texas, manufactures instruments used in human cell research for drug development. The Company is renowned for its scientific and technical staff, collaborative partnerships with leading pharmaceutical Companies and strategic alliances with key groups and academic institutions. CytoBioscience has a current order backlog of approximately $6 million, mostly in contract research work.
Dr. Carl Schwartz, Chief Executive Officer at Skyline, stated that this merger is a transformative move for Skyline. It would help accomplish the goal of broadening Skyline's business and would also bring in immediate and meaningful revenue. Moreover, it would also provide Skyline access to a host of important medical center customers and relationships, including a Who's Who in pharmaceutical product development. The Company can thereby leverage this platform for increasing awareness about its STREAMWAY System and thus boost sales.
Merger to Close by End of October
- The Company revealed that it has submitted all requisite paperwork to NASDAQ for review. It is, however, subject to additional financial and due diligence documentation that is being done by third parties and is expected to be submitted in the coming weeks.
- Skyline anticipates that the merger would get completed by October 31, 2017.
About the Revolutionary STREAMWAY System
Skyline's proprietary STREAMWAY System is the first true direct-to-drain fluid disposal system. It has been specially designed for medical applications such as radiology, endoscopy, urology, and cystoscopy procedures. STREAMWAY System, which has already been approved by the FDA, directly connects to a facility's plumbing system to automate the collection, measurement as well as disposal of waste fluids. As on June 30, 2017, Skyline Medical customers have installed 103 STREAMWAY Systems in 52 facilities across 20 states and in Canada.
The main advantage of the STREAMWAY system is that it minimizes human intervention for better safety. In fact, it also improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. Besides, it offers unlimited capacity for increased efficiency in the operating room. This, in turn, leads to greater profitability.
Additionally, the STREAMWAY removes canisters and thus decreases overhead costs. It also delivers greater environmental stewardship by helping to remove the nearly 50 million potentially disease-infected canisters that go into landfills annually in the US.
Skyline's Marketing Initiatives for STREAMWAY
Skyline is gratified with the new marketing strategy which was implemented in the latter half of 2016 by the new management team.
- Lately, the Company focused its marketing message on STREAMWAY's competitive advantages for infection control as well as its utility in radiology procedures.
- Skyline participated in important national and local radiology conferences, wherein it received the support and validation of major Group Purchasing Organizations.
- Moreover, the Company has also initiated dialogue with potential customers including those with multi-hospital networks as well as a hospital that could serve as a Center of Excellence for STREAMWAY. This center would facilitate the observation of procedures concerning STREAMWAY by prospective customers.
- Besides, it is also pursuing distribution agreements in Europe and Canada and envisages having one or more agreements in place during the fourth quarter.
Strong Growth Prospects for Skyline
Skyline is also pleased with its continued progress in the third quarter of this year. In fact, it intends to report its third-quarter financial results by mid-November 2017.
Dr. Carl Schwartz mentioned that Skyline is currently in a good position and its growth prospects have never been stronger. This can be attributed to the forthcoming completion of the merger with CytoBioscience as well as an improving outlook for its STREAMWAY business. He shared that the Company has worked very hard with its limited staff and a tight budget to increase awareness about STREAMWAY's capabilities and safety features. The efforts are now beginning to show results.
Last Close Stock Review
On Monday, October 02, 2017, the stock closed the trading session at $1.49, climbing 2.50% from its previous closing price of $1.45. A total volume of 284.75 thousand shares have exchanged hands, which was higher than the 3-month average volume of 271.65 thousand shares. Skyline Medical's stock price advanced 6.43% in the last one month and 2.05% in the previous three months. The stock currently has a market cap of $9.12 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily